[Treatment strategy for pediatric Hodgkin lymphoma]

Pediatric Hodgkin lymphoma (HL) is a malignant disease that arises from lymphoid reticulum cells, which can metastasize to the spleen, liver, and bone marrow, including the lymph nodes. Classic HL is characterized by the presence of CD30-positive Hodgkin Reed-Sternberg (HRS) cell proliferation. Its symptoms include fever, night sweats, weight loss, itching, splenomegaly, and hepatomegaly, along with painless lymphadenopathy. Although HL has long achieved a high cure rate, late complications such as cardiac complications, infertility, and secondary cancers still pose a threat. The current treatment standard includes a combination of multiagent chemotherapy and low-dose radiation therapy, and attempts have been made to establish a regimen that omits radiation therapy in patients who respond well to initial therapy. The introduction of new molecular-targeted agents is expected to result in further treatment reduction.